Intravenous Fibrinolysis for Central Retinal Artery Occlusion A Cohort Study and Updated Patient-Level Meta-Analysis
Intravenous Fibrinolysis for Central Retinal Artery Occlusion A Cohort Study and Updated Patient-Level Meta-Analysis
复制标题
DOI：
10.1161/strokeaha.119.028743
复制
发表时间：
2020-07-01
期刊：
影响因子：
8.3
通讯作者：
Schrag, Matthew
中科院分区：
文献类型：
--
作者：
Mac Grory, Brian;Nackenoff, Alex;Schrag, Matthew
背景和目的：视网膜中央动脉阻塞会导致患眼突然、无痛、通常是永久性的视力丧失。目前还没有经过证实的有效治疗方法来挽救视力，并且对有效治疗的需求明显未得到满足。在这项工作中，我们评估了静脉注射组织型纤溶酶原激活剂（IV阿替普酶）的疗效在一项前瞻性队列研究和更新的系统评价和荟萃分析。方法：我们纳入了连续的急性视网膜中央动脉阻塞患者，这些患者在症状发作48小时内，
Background and Purpose: Central retinal artery occlusion results in sudden, painless, usually permanent loss of vision in the affected eye. There is no proven, effective treatment to salvage visual acuity and a clear, unmet need for an effective therapy. In this work, we evaluated the efficacy of intravenous tissue-type plasminogen activator (IV alteplase) in a prospective cohort study and an updated systematic review and meta-analysis. Methods: We enrolled consecutive patients with acute central retinal artery occlusion within 48 hours of symptoms onset and with a visual acuity of